Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma

Kudo, Masatoshi

doi:10.1159/000173422

Cited by 23 publications

(24 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As secondary prevention, IFN treatment to eradicate the virus following curative resection and ablation, and maintenance IFN treatment [36] are known to significantly reduce the cancer recurrence rate and to improve the prognosis [37]. The direct growth inhibitory action of IFN to the HCC cells has also been proved in vitro [38].…”

Section: Primary and Secondary Inhibition Of Hepatocarcinogenesismentioning

confidence: 99%

“…Additional local ablation following transarterial treatment (lipiodol TACE or transcatheter arterial infusion) may increase curability. IFN therapy after curative therapy has proved to be useful for improving patient survival [37]; therefore, it is recommended to treat patients who can tolerate IFN therapy. In the future, even sorafenib may be a first choice of treatment for adjuvant therapy if positive results are obtained by ongoing global clinical trials (fig.…”

Section: Impact Of Sorafenib On Treatment Algorithm Of Hccmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy

Kudo

2008

Oncology

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignant tumor which is becoming more prevalent worldwide. Patients at high risk of developing HCC, namely hepatitis B- and C-related liver cirrhosis patients, should be entered into surveillance programs, which should be performed using both ultrasonography and 3 tumor markers (AFP, PIVKA-II, AFP-L3). The surveillance interval needs to be shortened for patients at higher risk of HCC. Therefore, super-high-risk patients should be screened at 3- to 4-month intervals based on their risk of developing HCC. Sonazoid-enhanced US is extremely useful to characterize hepatic tumors when compared with multidetector-row computed tomography (MDCT). Moreover, Sonazoid-enhanced US with defect reperfusion imaging is a breakthrough approach in the treatment of HCC. This technique will markedly change the therapeutic strategy for liver cancer. Furthermore, diagnostic capability using the new imaging technique Gd-EOB-DTPA MRI is promising. A reduced uptake (low intensity) in the hepatobiliary phase of Gd-EOB-DTPA MRI strongly suggests HCC (including early-stage HCC) or a high-grade dysplastic nodule with high malignant potential. Empirically, intrahepatic arterial infusion chemotherapy using implanted reservoir port is known to be effective for advanced HCC with vascular invasion; however, no randomized study exists to prove its efficacy. Further controlled study is necessary to establish this treatment option as a standard of care in a treatment algorithm for HCC. In contrast, sorafenib was established as the first choice of treatment as a standard of care in advanced HCC patients with preserved liver function and vascular invasion/extrahepatic spread. Furthermore, global clinical trials are now ongoing using sorafenib as an adjuvant setting after resection, ablation or TACE. Efficacy of combined use of sorafenib with TACE or intra-arterial infusion chemotherapy is not clear. In order to clarify this issue a randomized clinical trial for intermediate and advanced HCC comparing sorafenib alone versus sorafenib combined with maintenance TACE/intra-arterial infusion chemotherapy and/or intra-arterial infusion chemotherapy is scheduled to be initiated in Japan in 2009. If positive results are obtained by these trials, its impact on treatment strategy for HCC will be drastically changed.

show abstract

Section: Primary and Secondary Inhibition Of Hepatocarcinogenesismentioning

confidence: 99%

Section: Impact Of Sorafenib On Treatment Algorithm Of Hccmentioning

confidence: 99%

Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy

Kudo

2008

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of a meta-analysis demonstrated that IFN therapy appears to be effective after curative treatment for HCC in HCV patients because of improved survival and lower recurrence rates (96). However, the authors caution the routine use of IFN cannot be advocated based upon the available evidence because the studies included in the analysis were heterogeneous and in some cases benefits of IFN were only demonstrated in subgroup analyses.…”

Section: Ifn After Liver Resection or Ablation To Prevent Or Treat Rementioning

confidence: 99%

Viral hepatitis and hepatocellular carcinoma: etiology and management

Zamor

deLemos

Russo

2017

J. Gastrointest. Oncol.

127

102

View full text Add to dashboard Cite

Hepatitis B virus (HBV) risk and hepatocellular carcinoma (HCC) EpidemiologyIt is estimated that over 50% of HCC cases worldwide are related to chronic HBV (1,2). Since the implementation of worldwide HBV vaccination there has been an overall decline in the burden of HBV, yet the HBV burden remains quite high in various parts of the world. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths (3). The annual incidence of HCC is estimated to be <1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. Because of worldwide and geographic variations in HBV incidence, the burden of HBV related HCC also varies. Asian-Pacific and sub-Saharan Africa represent the highest incidence of HCC worldwide. Much lower risk of HBV associated HCC is seen in the United States with less than 20% incidence. Due to its diversity, Europe has different areas: low risk (18%) in West and North and high risk (51%) East and South (4). Occult HBV or subclinical infection as defined by detectable HBV DNA in the liver but hepatitis B surface antigen (HBsAg) seronegativity is now recognized as increased risk for HCC. The risk is most notable in those over the age of 50 (5,6). Recently published data reveal that in China, the age-standardized death due to HBV-related HCC and cirrhosis in 2013 was 10.95 and 4.91 per 100,000 people (7). Fifty-five percent of all HCC cases worldwide are reported from China (8).In 1991, the WHO recommended the integration of the HBV vaccine into national immunization programs in countries with an HBV carrier prevalence of 8% or higher by 1995 and in all other countries by 1997 (9). The universal infant vaccination rate in sub-Saharan Africa was initially quite low at 5% in 2000 but increased to 72% by 2012. Parts of the Pacific region had the lowest immunization rates, but by 2012 had increased to the highest rates at 91%. Taiwan has an exceptionally higher This review outlines the various mechanisms and pathophysiology that contributes to this process. There will also be a review on the recommended screening for HCC. Treatment considerations, which are different for these viruses, will be outlined in this review.

show abstract

“…Peg-IFN may exert its antiangiogenic activity through VEGF suppression, by down-regulating HIF-1a expression and inhibition of the phosphatidylinositol-3 kinase and/or mitogen-activated protein kinase signaling pathways. 36 In addition, Peg-IFN reduces proliferating cell nuclear antigen and G1 cyclin expression; thus, it has a stronger effect on growth inhibition and apoptosis. In accordance with the given mechanism, our Peg-IFN group in the current study had significantly a lower postoperative recurrence rate of HCC than the control group, although both groups had MTA1-positive HCC and had a high risk of recurrence.…”

Section: Original Articlementioning

confidence: 99%

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Lee

Chung

Kim

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND: Metastatic tumor antigen 1 (MTA1) overexpression is closely associated with postoperative recurrence of hepatocellular carcinoma (HCC). It has been suggested that pegylated interferon (Peg-IFN) can prevent the occurrence of HCC in patients who have chronic viral hepatitis. In this study, the authors examined whether postoperative adjuvant Peg-IFN therapy can reduce the recurrence of MTA1-positive HCC after curative surgical resection. METHODS: In this case-control study, 93 patients with MTA1-positive HCC who underwent curative surgical resection were prospectively enrolled. The median patient age was 53 years (range, 27-78); there were 65 men and 28 women; the etiology was hepatitis B virus (HBV) in 77 patients, hepatitis C virus (HCV) in 6 patients, and non-HBV/non-HCV in 10 patients; 31 patients received Peg-IFN (Peg-INTRON V R ) subcutaneously at a dose of 50 lg per week for 12 months (the Peg-IFN group); and the remaining 62 patients were followed only and did not receive any adjuvant therapies (control group). Patients were followed every 1 to 3 months for a median of 24 months. RESULTS: HCC recurred postoperatively in 26 of 93 patients (28%), and 9 patients (10%) died during follow-up. The overall cumulative recurrence rates were significantly lower in the Peg-IFN group than in the control group (7% and 14% vs 24% and 34% at 1 year and 2 years, respectively; P <.05). In addition, the 1-year and 2-year cumulative survival rates were higher in the Peg-IFN group compared with the control group (100% vs 93% and 100% vs 87%, respectively; P <.05). In multivariate analysis, the receipt of adjuvant Peg-IFN therapy, in addition to having a lower Cancer of the Liver Italian Program score and being a woman, was an independent, favorable factor for a lower risk of postoperative recurrence. INTRODUCTIONHepatocellular carcinoma (HCC) is characterized by its high prevalence and aggressiveness, which accounts for a major cause of death in the Far East and in sub-Saharan Africa. 1,2 Clinically, only less than 10% to 20% of patients with HCC have previously been considered candidates for surgical resection. 3-5 Furthermore, frequent marginal or remote recurrence of HCC in the remnant liver is another insurmountable problem in light of long-term prognosis. 6,7 According to previous studies, postoperative recurrence rates after surgical resection reached approximately 50% to 80%, whereas our recent studies reported relatively lower recurrence rates. [8][9][10][11][12] Metastatic tumor antigen 1 (MTA1) plays an important role in the tumorigenesis and metastasis of various human malignancies, such as liver, breast, prostate, lung, colorectal, and gastric cancers. 13,14 Our recent study demonstrated that MTA1 overexpression is associated with frequent postoperative recurrence as well as microvascular invasion compared with negative MTA1 status and, consequently, can be used a valuable predictor of worse postoperative outcomes for patients who have HCC with respect to recurrence and survival. 15 Such findings are i...

show abstract

Impact of Interferon Therapy after Curative Treatment of Hepatocellular Carcinoma

Cited by 23 publications

References 102 publications

Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy

Hepatocellular Carcinoma 2009 and Beyond: from the Surveillance to Molecular Targeted Therapy

Viral hepatitis and hepatocellular carcinoma: etiology and management

Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1‐positive hepatocellular carcinoma

Contact Info

Product

Resources

About